Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Patent metadata

Field	Value
Publication number	US-11872229-B2
Application number	US-202017082747-A
Country	US
Kind code	B2
Filing date	Oct 28, 2020
Priority date	Jun 29, 2016
Publication date	Jan 16, 2024
Grant date	Jan 16, 2024

Abstract

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

First claim

What is claimed is:

1. A modified release solid oral dosage form comprising:
(a) a core composition comprising a (E) isomer, a (Z) isomer, a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, (S)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, or a mixture of (R) and (S) isomers of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (Compound I) having the structure:

where *C is a stereochemical center, or a pharmaceutically acceptable salt thereof;
wherein the core composition comprises by weight:
about 6% to about 20% of Compound (I) or a pharmaceutically acceptable salt thereof;
about 34% to about 72% of microcrystalline cellulose;
about 5% to about 25% mannitol;
about 0% to about 20% of hydroxypropyl methyl cellulose;
about 0.5% to about 1.5% of crosslinked homopolymer of N-vinyl-2-pyrrolidone; and
about 0.5% to about 1.5% of sodium stearyl fumarate;
(b) a sub-coating layer coating the core composition, the sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and
(c) an enteric coating layer encapsulating the sub-coating layer and the core composition, the enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone.

2. The modified release solid oral dosage form of claim 1 , wherein the cellulose derivative is selected from cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose, hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose succinate (HPMCS), and hydroxypropylmethylcellulose acetate succinate (HPMCAS).

3. The modified release solid oral dosage form of claim 1 , wherein:
the sub-coating layer comprises a polyvinyl alcohol; and
the enteric coating layer comprises a poly (methacrylic acid-co-ethyl acrylate) copolymer.

4. The modified release solid oral dosage form of claim 3 , wherein the polyvinyl alcohol is a pigmented polyvinyl alcohol.

5. The modified release solid oral dosage form of claim 1 , wherein:
the modified release solid oral dosage form releases less than about 10% by weight of Compound (I) or a pharmaceutically acceptable salt thereof in less than two hours at a pH less than or equal to about 2.0;
at least about 80% by weight of Compound (I) or a pharmaceutically acceptable salt thereof in about 15 minutes to about two hours at a pH equal to or more than about 6.0; and
any unreleased amount of Compound (I) is released by the end of about 7.5 hours at a pH equal to or more than about 6.0.

6. The modified release solid oral dosage form of claim 1 , wherein the core composition comprises Compound (I).

7. The modified release solid oral dosage form of claim 1 , wherein Compound (I) or a pharmaceutically acceptable salt thereof is an (E) and (Z) mixture of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

8. The modified release solid oral dosage form of claim 1 , wherein at least about 85% by weight of Compound (I) or a pharmaceutically acceptable salt thereof is the (E) isomer.

9. The modified release solid oral dosage form of claim 1 , wherein at least about 90% by weight of Compound (I) or a pharmaceutically acceptable salt thereof is the (E) isomer.

10. The modified release solid oral dosage form of claim 1 , wherein Compound (I) or a pharmaceutically acceptable salt thereof is a substantially pure amorphous form.

11. The modified release solid oral dosage form of claim 1 , wherein the core composition comprises about 30 mg to about 100 mg of Compound (I) or a pharmaceutically acceptable salt thereof.

12. The modified release solid oral dosage form of claim 1 , wherein the core composition further comprises at least one excipient selected from fillers, drug release modifiers, disintegrants, and lubricants.

13. The modified release solid oral dosage form of claim 1 , wherein the core composition weighs about 83% to about 91% of the total weight of the modified release solid oral dosage form.

14. The modified release solid oral dosage form of claim 1 , wherein the sub-coating layer weighs about 2% to about 4% by weight of the modified release solid oral dosage form.

15. The modified release solid oral dosage form of claim 1 , wherein the enteric coating layer further comprises a solubilizer and a plasticizer/anti-tacking agent.

16. The modified release solid oral dosage form of claim 1 , wherein the enteric coating layer weighs about 6% to about 20% of the total weight of the modified release solid oral dosage form.

17. The modified release solid oral dosage form of claim 1 , wherein the enteric coating layer comprises by total weight of the modified release solid oral dosage form:
about 5% to about 16% of EUDRAGIT® L 30 D-55 or EUDRAGIT® L 100-55;
about 1% to about 3% of PlasACRYL™ T20; and
about 0.3% to about 0.8% of Polysorbate 80.

18. The modified release solid oral dosage form of claim 1 , wherein the core composition weighs about 80% to about 91% of the total weight of the modified release solid oral dosage form.

Assignees

• Principia Biopharma Inc

Inventors

• Ferdous Abu J
• Masjedizadeh Mohammad R
• Lin Wu

Classifications

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K9/2018

  Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates · CPC title

• A61K9/2846

  Poly(meth)acrylates · CPC title

• A61K9/2866

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61K9/2886

  having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209) · CPC title